Sacubitril/valsartan

CAS 1360873-85-3 23 current recordsSmall Molecule

Who holds supplier records for Sacubitril/valsartan? 23 organisations hold a current record for Sacubitril/valsartan: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (12), China (10) and Netherlands (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records

Cite as: PharmaTek, “Sacubitril/valsartan: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/sacubitril-valsartan

Reading the evidence

  • 23 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 12 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (23)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Sacubitril/valsartan. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Sacubitril/valsartan sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Overview

Sacubitril/Valsartan is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, used to reduce the risk of cardiovascular death and hospitalization for heart failure patients with reduced ejection fraction. This combination enhances the protective neurohormonal systems of the heart while suppressing the harmful systems, promoting vasodilation and blood pressure reduction.

Chemical identity

IUPAC name
4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
Canonical SMILES
CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O.CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O
InChIKey
XTKIDERFOUYBDE-QEPKIHTBSA-N
Synonyms
Calquence API, lcz-696 free acid, sacubitril valsartan

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Angiotensin 2 Receptor Blocker
Mechanism of action
Angiotensin 2 Receptor Antagonists

Therapeutic areas

Cardiovascular DiseasesHeart FailureHypertension

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Sacubitril/valsartan?

23 organisations hold an active US FDA Type II Drug Master File or a CEP for Sacubitril/valsartan: AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD) (India), CHANGZHOU PHARMACEUTICAL FACTORY (China), HONOUR LAB LTD (India), LEE PHARMA LTD (India), Alembic Pharmaceuticals Limited (India), AMI LIFESCIENCES PRIVATE LTD (India), CHROMO LABORATORIES INDIA PRIVATE LTD (India) and Dr. Reddy's Laboratories Ltd. (India), and 15 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Sacubitril/valsartan Drug Master Files are active?

AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD) (DMF 39628, 40981), CHANGZHOU PHARMACEUTICAL FACTORY (DMF 35480, 43974), HONOUR LAB LTD (DMF 33657, 42543), LEE PHARMA LTD (DMF 41246, 39023), Alembic Pharmaceuticals Limited (DMF 33570), AMI LIFESCIENCES PRIVATE LTD (DMF 37994), CHROMO LABORATORIES INDIA PRIVATE LTD (DMF 39929) and Dr. Reddy's Laboratories Ltd. (DMF 31574) and 15 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

How do I qualify a Sacubitril/valsartan supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Sacubitril/valsartan?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.